London is to trial a new pilot scheme that will see the temporary suspension of arrests of 18 to 24-year-olds for the possession of small amounts of cannabis.
A report leaked to The Telegraph has shown that the Mayor of London, Sadiq Khan, is considering the launch of a pilot scheme that will divert low-level offenders away from the criminal justice system.
The pilot, which is based on the successful Thames Valley Model which won a national award last year, will see positive interventions for young people caught in possession of small amounts of cannabis. According to the leaked report, they will be referred to courses or counselling instead of being arrested.
The leak also suggested that the areas of London that will be taking part in the trial include Bexley, Lewisham and Greenwich. The results of the pilot would be subject to an evaluation prior to an official roll-out.
It is hoped that the scheme will help to reduce drug-related crime in the city.
A spokesperson for the Mayor of London has highlighted that the funding for the pilot scheme has not had final approval from the Mayor’s Office for Policing and Crime (MOPAC), and that the Mayor does not have the legislative power to decriminalise cannabis.
The spokesperson commented: “This limited trial, which is still in development and has yet to be approved by City Hall, would involve three of London’s 32 boroughs and would only apply to 18 to 24-year-olds found in possession of a small amount of cannabis. It would not apply to any other drug.
“The idea of the scheme, which is already used by other police forces across the country, would be to divert young people who are found with a small amount of cannabis away from the criminal justice system and instead provide help and support. This has been shown to reduce reoffending.
“Reducing crime is the Mayor’s top priority and he will continue to explore and implement the most effective solutions to help to divert young people away from drug use and crime for good.”
The new pilot scheme was suggested by a consultancy report commissioned by Lewisham and produced by drug reform group Volteface into the negative impacts of low-level drug offences.
According to the spokesperson, Lewisham approached MOPAC, which is actively involved in discussions around the scheme, to request support, although the pilot has not yet been finalised.
Volteface, which released a report in 2021 suggesting that the UK should take control of the medical cannabis and CBD markets to provide an economic boost for the UK, has said that policymakers must adopt evidence-based diversion schemes.
Volteface director, Paul North, commented: “The combination of socio-economic conditioning and policing strategy can result in a divisive relationship between communities and the police, causing psychological, punitive and societal damage.
“Putting young people into the criminal justice system does not address the root causes of why someone might be in possession of drugs and leave a criminal justice footprint can have significant implications on future prospects.
“It is therefore vital that policymakers up and down the UK adopt evidence-based diversion schemes to provide an opportunity for effective intervention and education, providing a crucial pathway away from further criminality.
“Volteface has been working with key policymakers in London, and although it is disappointing that information has been leaked to the press, we look forward to sharing future developments in the coming weeks.”
The Guardian reported in April 2021 that Khan would consider decriminalising cannabis in the capital should he be re-elected on May 6, and Khan set out in his manifesto that he would establish a London Drug Commission of independent experts who will examine the effectiveness of drugs laws with a particular focus on cannabis.
In 2021, the London Cannabis Legalisation Commission called for a trial of legal cannabis in London after it released its London Cannabis Study, recommending the legalisation of the plant in order to reduce violence and provide resources to reinvest into youth services.
Speaking to Cannabis Wealth’s sister title, Cannabis Health, in an exclusive interview, Hamish Stewart, chair of the London Cannabis Legalisation Commission, said that legalising cannabis in London is “a huge opportunity and you dampen the violence linked to the illicit drug trade.”
Stewart commented on the potential pilot scheme to say: “I think it is a great start but London has a lot of catching up to do if you consider that Luxembourg decriminalised cannabis and Germany is going to proceed with retail legalisation. So, hopefully, this is just the first step of London showing more meaningful leadership to catch us up with the rest of the world.
“Really, what’s encouraging here is that you see local councils leading the way and hopefully across the UK this can inspire more collaboration with the councils on how to decriminalise cannabis and then really kickstart some local production.
“London and the UK is already one of the world’s largest growers and exporters of medical-grade cannabis and so the production systems to grow cannabis for medical research applications, industrial use and retail use are already well established. So, London has the opportunity to bring some of that knowledge into the city and start producing for local needs. There is already production facilities in London for medical applications, so, we just need to open that up for retail.
“My motivation in starting the Cannabis Commission arose after watching some extreme violence in front of my home related to a drug deal gone bad and so we know that a large portion of the illicit drug trade in London is cannabis-related, and that is what is fuelling violence.
“So, it is time for all London policymakers to acknowledge that. If our political leaders are committed to reducing and ending extreme youth violence they need to legalise the cannabis trade because, in illegal industries, disputes are settled with violence in legal industries, and formal industries, you can have access to a lawyer for dispute resolution – because that is how disputes in the cannabis industry can be settled in the formal sector.
“And that is the motivation for Luxembourg and decriminalising cannabis. So, we really hope this is a first baby step, and then if you really want to reduce violence, it should be decriminalisation across London and giving people who are in the cannabis industry access to formal dispute resolution mechanisms.
“There is nowhere to go but up, and London and other UK cities can really build on the international experience of Canada, the US, New York State and a whole number of other jurisdictions which already have decriminalised for the legal cannabis market. And so, this is really about the start of a very rapid catching-up process.”
London had an approximate 56,000 reported drug offences in 2020/21, with most drug crimes consisting of possession offences.
Report calls for UK Government to turbocharge cannabinoid innovation
A new report has set out recommendations for the UK to become the global leader in cannabinoid innovation.
Drawing from expert insights, the report – From Containment to Nurturing: How the UK can become a world leader in cannabinoid innovation – was commissioned by The Centre for Medicinal Cannabis and the Association for the Cannabinoid Industry.
The report argues for the UK government to recognise the UK’s legal cannabis market, and to create a public policy and nurturing regulatory framework to foster its growth.
Highlighting that millions of Britons routinely purchase cannabis products as medicine and food supplements, it stipulates that the UK has the opportunity to harness its global strengths in life sciences to become a world leader in medicinal and nutraceutical cannabinoid innovation by adopting the report’s proposals and recommendations.
Authored by regulatory thinker Professor Christopher Hodges, the report will be launched with a speech by George Freeman MP, Minister for Science, Research & Innovation – the first ever ministerial address to the legal cannabis sector.
Included in the recommendations are calls for updates to hemp farming rules, modernisation of the Proceeds of Crime Act and the creation of a national patient registry for all cannabis based medicines prescribed in the UK.
Stewarding a new industry
The report draws on inputs from leading industry players, academics, patients, consumers and investors, and its authors state that regulations are critical issues in order to help set the UK apart as it decides the economic and political path it wants to adopt post-Brexit.
Hodges argues that the regulatory framework he sets out would achieve three important objectives:
● Global competitive advantage for the UK post-Brexit, helping the country to leverage its historic and economic strengths in a rapidly growing and unprecedented global industry
● Regulatory best practice giving early mover advantage, helping to pioneer new approaches to regulating a novel industry that other jurisdictions on a similar path can choose to emulate
● Scientific advances and innovations, with pioneering new treatments, manufacturing methods, and end user product innovations, helping the UK to reinforce its reputation as the home of world-leading inventions and discoveries that improve our environment, our health, and quality of life.
The report views the cannabinoid sector through the lens of Outcome-Based Cooperative Regulation, arguing that for regulations to be effective, they need to be based in trust and collaboration. It also urges the Government to establish a ‘stewarding’ authority to govern and guide the sector and implement the required reforms.
Professor Christopher Hodges, Emeritus Professor of Justice Systems at the Centre for Socio Legal Studies at the University of Oxford, commented: “The analysis in this report and the principles we have outlined lead us to recommend a series of policy changes to help bring about the positive and shared goals that we articulate.
“The recommendations are directed both at regulators and industry, with the understanding that both parties have an obligation to co-operate to steward this new industry and support it to develop in an innovative but also safe and responsible way.”
Key objectives of the report include:
- To build a strategic engagement with government and associated agencies – move from containment to nurturing
- To establish a footprint / landing zone for the sector within government i.e. Department for Business, Energy and Industrial Strategy (BEIS)
- To establish a new coherent regulatory framework for CBMPs and consumer cannabinoids in the UK
- To optimise the potential public funding opportunities for the sector
- To align ourselves with current government thinking with regard to future regulation
The UK has a global cannabinoid leader
With cannabinoids making up a rapidly accelerating global industry, the report highlights that the UK holds an advantage in that it can learn from the successes and failures of other comparable regimes.
It also states that Brexit has given the UK the “freedom to choose to align or differentiate itself from the markets with which it is competing” such as hemp cultivation and CBD regulation.
Addressing the country’s potential to be a sector leader, the report encourages the creation of a UK ‘Centre of Excellence’ to advance the evidence base for cannabinoids and their applications, which it says could be established with the support of major universities.
Whilst the UK has set out its Life Sciences Vision, aiming to make the country a global leader in the sector post-Brexit, the report highlights how the cannabinoid sector can help accelerate this ambition.
Ir recommends that an incubator and cannabinoid innovation fund for UK pilot studies is created in areas aligned with the government’s R&D strategy to support key areas like life sciences and new agri-tech opportunities.
“By adopting the proposals and recommendations laid out here, the UK can inaugurate a timely opportunity to harness its global strengths in life sciences to become a world leader in medicinal and nutraceutical cannabinoid innovation,” state Steve Moore and Paul Birch, co-founders of the CMC and ACI.
Attracting investment into the UK
With the government having neglected to provide the right regulatory and grant support, the report highlights that those working in the sector feel restricted and shut out of policy engagement. It notes this has led to a situation whereby the UK’s sector is struggling to “find its feet” in the international market.
The recommendations in the report intent to provide a vision that “moves beyond a policy of control and containment to one of support and stewardship”. As well as helping to advance scientific discovery and innovation, and improve well-being, this will also help to create jobs and investment in local economies.
One recommendation that address this issue is modernising the Proceeds of Crime Act, which currently prohibits dealing with any benefit arising from criminal conduct, even when that activity occurs abroad if that same activity would be illegal if it occured in the UK.
This is a step that has already been taken on the island of Jersey, where people are permitted to do business in the cannabis sector as long as it is legal where it is taking place.
The report suggests that the UK’s Proceeds of Crime Act should be updated to create an explicit exemption for private enterprise by entities operating in legal jurisdictions – modelled on the changes already incorporated into law in Jersey.
The report states: “The seeds are there for rapid growth but it cannot happen without a clear strategy built upon co-ordinated government stewardship and the ambition to not just tolerate, but actively nurture the sector to expand and mature, so it attracts more investment, jobs and innovations, and secures political support and public recognition.”
It goes on to say: “Until such time as the POCA regime is clarified to exempt the owners and operators and those who gain (including shareholders) from the activities of legal companies in the UK, major institutional investors will be deterred from committing to the sector.”
Blair Gibbs, Senior Associate, Centre for Medicinal Cannabis/Association for the Cannabinoid Industry, commented: “Our conclusion from this research is not that the UK’s legal cannabis sector is over-regulated, or merely suffering from outdated rules, or simply needs red tape and unwarranted regulations to be stripped back.
“The regulations encompassing the cannabis sector are wide-ranging and complicated, but right now are also uncalibrated to the risks associated with each product.”
The report has also recommended that GP are enabled to prescribe medical cannabis. To find out more about this recommendation please visit our sister site: www.cannabishealthnews.co.uk.
CLIMB Act aims to give cannabis businesses access to financial capital
The new Act will allow US cannabis businesses to list on stock exchanges.
Representatives Troy Carter and Guy Reschenthaler have introduced the Capital Lending and Investment for Marijuana Businesses Act (CLIMB Act) to help improve access to services for legitimate cannabis-related businesses.
This legislation would give US cannabis companies access to lending and grant opportunities from both financial institutions and government agencies.
The US cannabis industry has been growing at a rapid rate, but due to the federal prohibition of cannabis, cannabis businesses in the US are currently struggling to access capital through traditional routes.
Federal prohibition also prevents US cannabis businesses from listing on US exchanges. However, global companies are currently permitted to list, giving them an unfair advantage over US cannabis businesses to secure critical capital.
The CLIMB Act aims to permit access to community development, small businesses, minority development and financial institution capital for investment and financing of cannabis-related businesses.
This includes business assistance, such as access to financial services, insurance/surety products, debt or equity capital, accounting services and more, as well as safe harbour for businesses to list on stock exchanges.
If passed, the bill could generate an estimated $22.7bn in tax revenue through increased investment.
Congressman Troy Carter stated: “The bipartisan CLIMB Act is a huge opportunity to bring equity and equal opportunity into our nation’s burgeoning cannabis industry.
“From my work on the Small Business Committee and by working directly with small, minority, and veteran-owned cannabis businesses, it’s clear that access to capital remains one of the biggest barriers to entry and to success in the industry.
“By bringing symmetry into the business ecosystem with the CLIMB Act, we can help communities that have long been harmed by the criminalisation of marijuana move to now be leaders in the business sphere – and that’s what the American Dream is all about.”
It has been estimated that the CLIMB Act would bring in an expected $47.3bn in investments to support the growth and stability of US cannabis operators and ancillary businesses within the first year, and it is also projected to create 600,000 jobs by giving these businesses access to capital.
Reschenthaler also stated: “American cannabis companies are currently restricted from receiving traditional lending and financing, making it difficult to compete with larger, global competitors.
“The CLIMB Act will eliminate these barriers to entry, and provide state legal American cannabis companies, including small, minority, and veteran-owned businesses, with access to the financial tools necessary for success.
“This bipartisan legislation will boost the economy, create jobs, and level the playing field for American businesses.”
First vice chair of the National Cannabis Roundtable and CEO of Ilera Holistic, Dr Chanda Macias, stated: “The CLIMB Act will unleash the full potential of the American cannabis industry. This legislation will ensure that American cannabis businesses can access the lending and grant opportunities that other domestic industries currently enjoy, and it will make it easier for veteran, minority and women-owned businesses to compete by giving them access to a broad range of economic opportunities.
“I want to thank Congressmen Troy Carter and Guy Reschenthaler for introducing this important legislation.”
National Cannabis Industry Association CEO Aaron Smith, commented: “Small cannabis businesses cannot effectively compete in the highly regulated and complex cannabis industry without access to capital and lending services.
“This bill is a much-needed reform that will help level the playing field for main street cannabis businesses across the country.”
The bill could help to transform the US cannabis industry if it passes alongside the SAFE Banking Act, which has been designed to allow cannabis businesses access to traditional banking services, the HOPE Act, which aims to expunge past cannabis-related convictions, and the MORE Act, under which cannabis would be removed from the Controlled Substances Act’s list of scheduled substances and would remove criminal penalties for individuals manufacturing, distributing, or possessing the plant.
The SAFE Banking Act, however, which was last year included in the National Defense Authorization Act (NDAA) and then subsequently removed, has now been stalled in the Senate for sixth time.
Medical cannabis bill given green light in Spain
The Spanish Socialist Workers’ Party introduced a bill to regulate medical cannabis in the country in May.
To move patients away from the black market, Spain’s Subcommittee on medicinal cannabis in the Congress of Deputies has approved the bill aiming to regulate the use of cannabis for medicinal purposes.
Currently, it is illegal to sell cannabis in Spain. However, personal consumption on private residences is permitted. This means Spanish citizens that consume cannabis for medical purposes are often using the black market to access their medicine.
Although, cannabis-based medical products were not legal in the country, two cannabis medicines have been available to patients in Spain – GW Pharma’s oil products, Epidiolex and Sativex.
The new bill aims to give patients’ in Spain access to medical cannabis through hospitals and health centre pharmacies via medical specialists for a number of different conditions. Some of these conditions include multiple sclerosis-related pain, epilepsy, and symptoms related to chemotherapy and cancer pain.
According to local reports, the proposal has been supported by political parties including the socialist PSOE, United We Can, and Ciudadanos, PNV and PDECAT. The Canary reported that ERC and Bildu abstained, and the conservative PP and Vox voted against the proposals.
The non-profit organisation, The Spanish Observatory for Medical Cannabis (OECM), was established in the country in 2015 to “promote, coordinate and carry out activities and projects aimed at learning about the medicinal properties and uses of cannabis and its derivatives”.
The OECM stated: “From the OECM we are pleased with the agreement reached based on the report of conclusions of the medical cannabis subcommittee approved today by a majority thanks to UP, PSOE, Cs, PNV and PDeCAT. With the abstentions of ERC and Bildu and the votes against of PP and Vox.
“We started this journey in 2015 and after seven years we have achieved it. It has been an honour to fight for the rights of at least more than half a million patients who use medical cannabis. From the OECM we want to thank all the people who have worked to bring it forward, it is a giant first step for all of us.” [Translated from Google]
The proposed bill has been given the green light in parliament, however, it must still be voted on next week. If the bill wins the vote then the Spanish Agency of Medicines and Medical Products (AEMPS) will begin carrying out work on finalising regulations within the next six months.
The bill initially excluded cannabis flower, however, The Canary reports that the parties have included an amendment at the request of patients to use flower to develop “medicinal experimental projects” as “this way of using cannabis by inhalation provides faster effects for users than simply eating or drinking infusions”.